补阳还五汤加减治疗脑梗死患者的临床疗效及对血清胱抑素 C、 白细胞介素 -17A 的影响研究 *.

Objective: To investigate the clinical efficacy of Buyang Huanwu Decoction in the treatment of patients with cerebral infarction and the effect of serum cystatin C (Cys C) and interleukin (IL) -17A. Methods: 60 patients with cerebral infarction admitted to our hospital from January 2022 to December 2022 were selected as research objects and randomly divided into control group and observation group, with 30 cases in each group. The control group was given routine treatment, and the observation group was treated with Buyang Huanwu decoction on the basis of the control group. Before and after treatment, coagulation function indexes and cerebral hemodynamics indexes were detected, National Institutes of Health Stroke Scale (NIHSS) score and modified Barthel (BMI) score were performed, and the total clinical effective rate, serum Cys C and IL-17A expression levels before and after treatment and the occurrence of adverse reactions were compared between the two groups. Results: Compared with control group, the activated partial thrombin time (APTT) was longer and the level of fibrinogen (FIBObjective: To investigate the clinical efficacy of Buyang Huanwu Decoction in the treatment of patients with cerebral infarction and the effect of serum cystatin C (Cys C) and interleukin (IL) -17A. Methods: 60 patients with cerebral infarction admitted to our hospital from January 2022 to December 2022 were selected as research objects and randomly divided into control group and observation group, with 30 cases in each group. The control group was given routine treatment, and the observation group was treated with Buyang Huanwu decoction on the basis of the control group. Before and after treatment, coagulation function indexes and cerebral hemodynamics indexes were detected, National Institutes of Health Stroke Scale (NIHSS) score and modified Barthel (BMI) score were performed, and the total clinical effective rate, serum Cys C and IL-17A expression levels before and after treatment and the occurrence of adverse reactions were compared between the two groups. Results: Compared with control group, the activated partial thrombin time (APTT) was longer and the level of fibrinogen (FIB) was lower in observation group after treatment (P＜0.05) . Compared with the control group, the peak velocity (Vp) and average velocity (Vm) of the observation group were both larger, and the symmetry difference of peak velocity (DVp) and average velocity symmetry difference (DVm) of the observation group were smaller (P＜0.05) . Compared with control group, NIHSS score was lower and BMI score was higher in observation group after treatment, and the difference was significant (P＜0.05) .The total clinical effective rate of the observation group was 66.67%, higher than that of the control group 43.33% (P＜0.05) . Compared with control group,the expression levels of serum Cys C and IL-17A in observation group were lower after treatment (P＜0.05) . There was no difference in the incidence of adverse reactions between the two groups (P＞0.05) . Conclusion: Buyang Huanwu Decoction has significant clinical efficacy in the treatment of cerebral infarction patients, which can effectively improve the neurological function and quality of life of patients, reduce the expression level of serum Cys C and IL-17A, and is safe and reliable, worthy of further research and application.Objective: To investigate the clinical efficacy of Buyang Huanwu Decoction in the treatment of patients with cerebral infarction and the effect of serum cystatin C (Cys C) and interleukin (IL) -17A. Methods: 60 patients with cerebral infarction admitted to our hospital from January 2022 to December 2022 were selected as research objects and randomly divided into control group and observation group, with 30 cases in each group. The control group was given routine treatment, and the observation group was treated with Buyang Huanwu decoction on the basis of the control group. Before and after treatment, coagulation function indexes and cerebral hemodynamics indexes were detected, National Institutes of Health Stroke Scale (NIHSS) score and modified Barthel (BMI) score were performed, and the total clinical effective rate, serum Cys C and IL-17A expression levels before and after treatment and the occurrence of adverse reactions were compared between the two groups. Results: Compared with control group, the activated partial thrombin time (APTT) was longer and the level of fibrinogen (FIB) was lower in observation group after treatment (P＜0.05) . Compared with the control group, the peak velocity (Vp) and average velocity (Vm) of the observation group were both larger, and the symmetry difference of peak velocity (DVp) and average velocity symmetry difference (DVm) of the observation group were smaller (P＜0.05) . Compared with control group, NIHSS score was lower and BMI score was higher in observation group after treatment, and the difference was significant (P＜0.05) .The total clinical effective rate of the observation group was 66.67%, higher than that of the control group 43.33% (P＜0.05) . Compared with control group,the expression levels of serum Cys C and IL-17A in observation group were lower after treatment (P＜0.05) . There was no difference in the incidence of adverse reactions between the two groups (P＞0.05) . Conclusion: Buyang Huanwu Decoction has significant clinical efficacy in the treatment of cerebral infarction patients, which can effectively improve the neurological function and quality of life of patients, reduce the expression level of serum Cys C and IL-17A, and is safe and reliable, worthy of further research and application.Objective: To investigate the clinical efficacy of Buyang Huanwu Decoction in the treatment of patients with cerebral infarction and the effect of serum cystatin C (Cys C) and interleukin (IL) -17A. Methods: 60 patients with cerebral infarction admitted to our hospital from January 2022 to December 2022 were selected as research objects and randomly divided into control group and observation group, with 30 cases in each group. The control group was given routine treatment, and the observation group was treated with Buyang Huanwu decoction on the basis of the control group. Before and after treatment, coagulation function indexes and cerebral hemodynamics indexes were detected, National Institutes of Health Stroke Scale (NIHSS) score and modified Barthel (BMI) score were performed, and the total clinical effective rate, serum Cys C and IL-17A expression levels before and after treatment and the occurrence of adverse reactions were compared between the two groups. Results: Compared with control group, the activated partial thrombin time (APTT) was longer and the level of fibrinogen (FIB) was lower in observation group after treatment (P＜0.05) . Compared with the control group, the peak velocity (Vp) and average velocity (Vm) of the observation group were both larger, and the symmetry difference of peak velocity (DVp) and average velocity symmetry difference (DVm) of the observation group were smaller (P＜0.05) . Compared with control group, NIHSS score was lower and BMI score was higher in observation group after treatment, and the difference was significant (P＜0.05) .The total clinical effective rate of the observation group was 66.67%, higher than that of the control group 43.33% (P＜0.05) . Compared with control group,the expression levels of serum Cys C and IL-17A in observation group were lower after treatment (P＜0.05) . There was no difference in the incidence of adverse reactions between the two groups (P＞0.05) . Conclusion: Buyang Huanwu Decoction has significant clinical efficacy in the treatment of cerebral infarction patients, which can effectively improve the neurological function and quality of life of patients, reduce the expression level of serum Cys C and IL-17A, and is safe and reliable, worthy of further research and application.Objective: To investigate the clinical efficacy of Buyang Huanwu Decoction in the treatment of patients with cerebral infarction and the effect of serum cystatin C (Cys C) and interleukin (IL) -17A. Methods: 60 patients with cerebral infarction admitted to our hospital from January 2022 to December 2022 were selected as research objects and randomly divided into control group and observation group, with 30 cases in each group. The control group was given routine treatment, and the observation group was treated with Buyang Huanwu decoction on the basis of the control group. Before and after treatment, coagulation function indexes and cerebral hemodynamics indexes were detected, National Institutes of Health Stroke Scale (NIHSS) score and modified Barthel (BMI) score were performed, and the total clinical effective rate, serum Cys C and IL-17A expression levels before and after treatment and the occurrence of adverse reactions were compared between the two groups. Results: Compared with control group, the activated partial thrombin time (APTT) was longer and the level of fibrinogen (FIB) was lower in observation group after treatment (P＜0.05) . Compared with the control group, the peak velocity (Vp) and average velocity (Vm) of the observation group were both larger, and the symmetry difference of peak velocity (DVp) and average velocity symmetry difference (DVm) of the observation group were smaller (P＜0.05) . Compared with control group, NIHSS score was lower and BMI score was higher in observation group after treatment, and the difference was significant (P＜0.05) .The total clinical effective rate of the observation group was 66.67%, higher than that of the control group 43.33% (P＜0.05) . Compared with control group,the expression levels of serum Cys C and IL-17A in observation group were lower after treatment (P＜0.05) . There was no difference in the incidence of adverse reactions between the two groups (P＞0.05) . Conclusion: Buyang Huanwu Decoction has significant clinical efficacy in the treatment of cerebral infarction patients, which can effectively improve the neurological function and quality of life of patients, reduce the expression level of serum Cys C and IL-17A, and is safe and reliable, worthy of further research and application. was lower in observation group after treatment (P＜0.05) . Compared with the control group, the peak velocity (Vp) and average velocity (Vm) of the observation group were both larger, and the symmetry difference of peak velocity (DVp) and average velocity symmetry difference (DVm) of the observation group were smaller (P＜0.05) . Compared with control group, NIHSS score was lower and BMI score was higher in observation group after treatment, and the difference was significant (P＜0.05) .The total clinical effective rate of the observation group was 66.67%, higher than that of the control group 43.33% (P＜0.05) . Compared with control group,the expression levels of serum Cys C and IL-17A in observation group were lower after treatment (P＜0.05) . There was no difference in the incidence of adverse reactions between the two groups (P＞0.05) . Conclusion: Buyang Huanwu Decoction has significant clinical efficacy in the treatment of cerebral infarction patients, which can effectively improve the neurological function and quality of life of patients, reduce the expression level of serum Cys C and IL-17A, and is safe and reliable, worthy of further research and application. [ABSTRACT FROM AUTHOR]

目的：探讨补阳还五汤加减治疗脑梗死患者的临床疗效及对血清胱抑素 C(CysC)、白细胞介素(IL)-17A 的影响。方法：选择 我院自 2022 年 1 月至 2022 年 12 月接诊的 60 例脑梗死患者作为研究对象，随机分为对照组和观察组，各 30 例。对照组予以常 规治疗，观察组在对照组治疗的基础上，加用补阳还五汤加减治疗。在两组患者治疗前及治疗结束后，检测凝血功能指标和脑血 流动力学指标，进行美国国立卫生研究院卒中量表（NIHSS）评分、改良 Barthel（BMI）评分，比较两组临床总有效率、治疗前后血清 CysC、IL-17A 表达水平及不良反应发生情况。结果：对比对照组，观察组治疗后活化部分凝血酶时间（APTT）更长、纤维蛋白原 （FIB）水平更低（P<0.05）；对比对照组，观察组峰流速（Vp）、平均流速（Vm）均更大，峰流速对称性差值（DVp）、平均流速对称性差 值（DVm）均更小（P<0.05）；对比对照组，观察组治疗后 NIHSS 评分更低，BMI 评分更高，差异显著(P<0.05)；观察组临床总显效率 为 66.67%，高于对照组的 43.33%（P<0.05）；对比对照组，观察组治疗后血清 CysC、IL-17A 表达水平均更低（P<0.05）；两组不良反 应发生率比较，差异不显著（P>0.05）。结论：补阳还五汤加减治疗脑梗死患者的临床疗效显著，能够有效改善患者的神经功能和生 活质量，降低血清 CysC、IL-17A 表达水平，且安全性可靠，值得进一步研究应用。 [ABSTRACT FROM AUTHOR]